利妥昔单抗联合低剂量环磷酰胺及血浆置换治疗重症ANCA相关性血管炎
这项回顾性队列研究纳入64例危及生命的ANCA相关性血管炎患者,采用利妥昔单抗、低剂量静脉环磷酰胺、口服糖皮质激素和血浆置换联合方案。6个月时94%患者达到疾病缓解,需要透析者中67%恢复独立肾功能;长期随访中患者生存率85%,69%未进展至终末期肾病。联合治疗与持续B细胞耗竭和低复发率相关,严重感染率为0.28次/患者/年。
要点
- 联合方案在重症ANCA血管炎中6个月缓解率达94%。
- 需要透析者中67%恢复独立肾功能,长期69%未进展至ESKD。
- 36个月时87%患者持续缓解,严重感染率0.28次/患者/年。
核心结论
- 联合免疫抑制治疗可能允许避免糖皮质激素,并在重症ANCA相关性血管炎中提供快速持久的疾病控制。
研究设计与样本
- 回顾性队列研究,纳入64例危及生命的ANCA相关性血管炎患者。
主要发现
- 入组时中位eGFR为9 mL/min,47%需要透析,52%有弥漫性肺泡出血。
- 6个月时94%患者达到疾病缓解(BVAS version 3为0),需要透析者中67%恢复独立肾功能。
- 中位随访46个月期间,总体生存率85%,69%患者未进展至终末期肾病。
- 36个月时87%患者处于持续缓解,严重感染率为0.28次/患者/年。
关键数值与推荐
- 所有患者至少接受7次血浆置换。
- 6个月时利妥昔单抗、环磷酰胺和糖皮质激素的中位累积剂量分别为2 g、3 g和2.6 g。
临床怎么用
- 对合并弥漫性肺泡出血或严重肾功能受损的重症ANCA血管炎患者,可考虑利妥昔单抗、低剂量环磷酰胺、糖皮质激素和血浆置换联合方案。
局限性
- 为回顾性队列研究,与历史队列比较,非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis can present with life-threatening lung-kidney syndromes. However, many controlled treatment trials excluded patients with diffuse alveolar hemorrhage or severely impaired glomerular filtration rates, and so the optimum treatment in these cases is unclear. In this retrospective cohort study, we report the outcomes of 64 patients with life-threatening disease treated with a combination regimen of rituximab, low-dose intravenous cyclophosphamide, oral glucocorticoids, and plasma exchange. At entry, the median estimated glomerular filtration rate was 9 mL/min, 47% of patients required dialysis, and 52% had diffuse alveolar hemorrhage. All patients received a minimum of seven plasma exchanges, and the median cumulative doses of rituximab, cyclophosphamide, and glucocorticoid were 2, 3, and 2.6 g, respectively, at six months. A total of 94% of patients had achieved disease remission (version 3 Birmingham Vasculitis Activity Score of 0) at this time point, and 67% of patients who required dialysis recovered independent kidney function. During long-term follow-up (median duration 46 months), overall patient survival was 85%, and 69% of patients remained free from end-stage kidney disease, which compares favorably to a historic cohort with severe disease treated with a conventional induction regimen. Combination treatment was associated with prolonged B cell depletion and low rates of relapse; 87% of patients were in continuous remission at month 36. The serious infection rate during total follow-up was 0.28 infections/patient/year, suggesting that combination treatment is not associated with an enduring risk of infection. Thus, we suggest that combination immunosuppressive therapy may permit glucocorticoid avoidance and provide rapid and prolonged disease control in patients with severe ANCA-associated vasculitis.
引用
- Gulati K, Edwards H, Prendecki M, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2021. PMID: 34560140. doi:10.1016/j.kint.2021.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。